Drawing for ELANIX

USPTO serial 79212480

ELANIX

Reviewed by CopyMark Law Group

Reg. 5634868Status 709
Filing date
Status date
Registration date
Dec 25, 2018
Examiner
MAYES, LAURIE ANN
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ELANIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Lisa M. DuRoss

Lisa M. DuRoss Harness, Dickey & Pierce, PLC5445 Corporate Drive, Suite 200Troy, MI 48098UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
003Cosmetic preparations, namely, preparations for cleaning, protecting and maintaining in good condition various parts of the human and animal body surface; cosmetic preparations for regeneration of the skin and mucous membranes; cosmetic preparations for personal useSECTION 71 - CANCELLED—
005Pharmaceutical, biological or biotechnological products for curing or treating dermatological, gynecological and orthopedic conditions namely, pharmaceutical preparations for treating dermatological, gynecological and orthopedic conditions; wound dressing containing foetal cell based/derived proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins; wound dressing containing foetal cell based/derived proteins for which the cells were cultured in conditions as to produce these proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins for orthopaedic implants; pharmaceutical, biological or biotechnological preparations, namely, specialty medicated cosmetic creams, wound dressings, implantable scaffolds comprising living tissue for enhancing therapy or maintaining tissue contour, and cell derivatives being stem cells for medical use for tissue regeneration; pharmaceutical, biological or biotechnological preparations for medical use for treatment ofgynecological illnesses; biological or biotechnological preparations for medical use for treatment of orthopedic injuries; Pharmaceutical, biological or biotechnological preparations for medical use for activating cellular functions namely, for treatment of foetal cell derived structural and adhesion proteins to alter immune responses or enhance wound healing, growth supplements for manufacturing of cell therapiesSECTION 71 - CANCELLED—
009Software for medical applications for diagnosing and monitoring tissue healing in dermatology, orthopedics, and gynecologySECTION 71 - CANCELLED—
010Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organically derived but non-living scaffold materials alone or in combination with cells or cell derivatives to protect the skin and heal skin related conditions, burns, ulcers, cuts, and surgical incisions; Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with non-living cell derivatives to protect the skin and heal skin related conditions burns, ulcers, cuts, and surgical incisions; Matrices for tissue regeneration in the nature of implantable dermatology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices for tissue regeneration in the nature of implantable gynecology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices for tissue regeneration comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration in the nature of implantable orthopedic scaffolds comprising artificial or non- living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regenerationSECTION 71 - CANCELLED—
040Custom manufacture of cosmetic preparations, pharmaceutical preparations and/or chemical preparations for use in industry, intermediate and finished formulations, and single constituents; Custom manufacture of biological tissue and of biotechnological products for use in research; Custom manufacture of cosmetics to order and according to customer requirements; Custom manufacture for others of biological production platforms, biotechnology production platforms for protein production, mammalian and human cells for protein production, organoid production for testing purposes, to order and according to customer requirementsSECTION 71 - CANCELLED—
042Scientific research consulting services provided by consultants in the fields of pharmaceutical, biological, biotechnological, medical and cosmetic research, preclinical and safety assessmentsSECTION 71 - CANCELLED—
044Medical services and providing of medical information in the medical field; Medical testing and analysis for diagnostic purposes; Medical consultation services provided by consultants relating to pharmaceutical, biological, biotechnological, cosmetic and medical productsSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 11, 2026INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jul 11, 2025C71TCANCELLED SECTION 71—
Dec 25, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jul 11, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 11, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 11, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jul 11, 2022EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Jul 11, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 11, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 11, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 26, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 5, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 5, 2019FIMPFINAL DISPOSITION PROCESSED—
Mar 25, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 5, 2019OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Dec 25, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 19, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 19, 2018OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Oct 9, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 9, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 6, 2018GPNXNOTIFICATION PROCESSED BY IB—
Sep 19, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 19, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Sep 19, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 4, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 31, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Aug 31, 2018ALIEASSIGNED TO LIE—
Aug 31, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 31, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 31, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 7, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 1, 2018GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Mar 1, 2018GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 1, 2018CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 14, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 13, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 13, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 1, 2017RFNPREFUSAL PROCESSED BY IB—
Aug 17, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 17, 2017RFRRREFUSAL PROCESSED BY MPU—
Aug 1, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 31, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 29, 2017RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Jul 24, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 23, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 18, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 14, 2017DOCKASSIGNED TO EXAMINER—
Jul 14, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 13, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance